Furuhjelm et al. found that LCn3PUFA supplementation resulted in reduced risk of IgE-associated eczema at both 1 year (45) and during the first 2 years of childhood (P = 0.06 in adjusted analyses) (46). The gene discussed is IGHE; the disease is Eczematoid dermatitis.